共 50 条
- [1] IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancerANNALS OF ONCOLOGY, 2020, 31 : S1148 - S1148Emens, L. A.Adams, S.Barrios, C. H.Dieras, V. C.Iwata, H.Loi, S.Rugo, H. S.Schneeweiss, A.Winer, E. P.Patel, S.Henschel, V.Swat, A.Kaul, M.Molinero, L.Chui, S. Y.Schmid, P.
- [2] IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancerANNALS OF ONCOLOGY, 2020, 31 : S1261 - S1262Iwata, H.Emens, L.Adams, S.Barrios, C. H.Dieras, V.Loi, S.Rugo, H. S.Schneeweiss, A.Winer, E. P.Patel, S.Henschel, V.Swat, A.Kaul, M.Molinero, L.Chui, S. S.Schmid, P.
- [3] Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (12) : 1083 - 1091Iwata, HirojiInoue, KenichiKaneko, KojiIto, YoshinoriTsugawa, KoichiroHasegawa, AyumiNakagawa, ShintaroKuratomi, HiroyasuTamura, Kenji
- [4] Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancerANNALS OF ONCOLOGY, 2020, 31 (05) : 582 - 589Adams, S.Dieras, V.Barrios, C. H.Winer, E. P.Schneeweiss, A.Iwata, H.Loi, S.Patel, S.Henschel, V.Chui, S. Y.Rugo, H. S.Emens, L. A.Schmid, P.
- [5] Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 StudyJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (08): : 1005 - 1016Emens, Leisha A.Molinero, LucianaLoi, ShereneRugo, Hope S.Schneeweiss, AndreasDieras, VeroniqueIwata, HirojiBarrios, Carlos H.Nechaeva, MarinaAnh Nguyen-DucChui, Stephen Y.Husain, AmreenWiner, Eric P.Adams, SylviaSchmid, Peter
- [6] Atezolizumab plus nab-paclitaxel as first line therapy in Japanese patients with TNBC: A subgroup analysis of IMpassion130ANNALS OF ONCOLOGY, 2019, 30Inoue, KenichiShimomura, AkihikoKaneko, KojiIto, YoshinoriTsugawa, KoichiroYamauchi, TeruoTsurutani, JunjiNiikura, NaokiSawaki, MasatakaDoihara, HiroyoshiMiyoshi, YasuoHasegawa, AyumiNakagawa, ShintaroKuratomi, HiroyasuIwata, Hiroji
- [8] Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Adams, SylviaDieras, VeroniqueBarrios, Carlos H.Winer, Eric P.Schneeweiss, AndreasIwata, HirojiLoi, SherenePatel, SheetalHenschel, VolkmarChui, Stephen Y.Rugo, Hope S.Emens, Leisha A.Schmid, Peter
- [9] Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130) (vol 49, pg 1083, 2019)JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (02) : 223 - 223Iwata, HirojiInoue, KenichiKaneko, KojiIto, YoshinoriTsugawa, KoichiroHasegawa, AyumiNakagawa, ShintaroKuratomi, HiroyasuTamura, Kenji
- [10] Impact of steroid premedication on atezolizumab (atezo)-induced immune cell activation: A comparative analysis of IMpassion130 and IMpassion131 peripheral blood mononuclear cells (PBMCs).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Molinero, LucianaGuan, XiangnanDeurloo, RegulaGozlan, YosiSharim, HilaEmens, Leisha A.Cameron, David A.Schmid, PeterMiles, DavidAdams, SylviaChui, Stephen Y.Mariathasan, SanjeevO'Shaughnessy, JoyceAndre, FabriceLoi, Sherene